financetom
Business
financetom
/
Business
/
Microvast Names Carl Schultz as Chief Financial Officer
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Microvast Names Carl Schultz as Chief Financial Officer
Apr 10, 2025 1:19 AM

04:10 AM EDT, 04/10/2025 (MT Newswires) -- Microvast Holdings ( MVST ) said late Wednesday it has appointed Carl Schultz as chief financial officer, effective around April 21.

Schultz most recently served as CFO of North America at Air Liquide.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
TIMELINE-Germany's Commerzbank has a bumpy history with big M&A
TIMELINE-Germany's Commerzbank has a bumpy history with big M&A
Sep 21, 2024
(Updates timeline originally published on Sept. 11 with latest developments) By Tom Sims FRANKFURT, Sept 18 (Reuters) - Commerzbank is poised to put CFO Bettina Orlopp in charge of talks with UniCredit when the German bank's supervisory board meets next week, two people with knowledge of the matter said, as the Italian rival considers a takeover. Commerzbank has, like some...
Musk's Neuralink gets FDA's breakthrough device tag for 'Blindsight' implant
Musk's Neuralink gets FDA's breakthrough device tag for 'Blindsight' implant
Sep 21, 2024
(Reuters) -Elon Musk's brain-chip startup Neuralink said on Tuesday its experimental implant aimed at restoring vision received the U.S. Food and Drug Administration's breakthrough device designation. The FDA's breakthrough tag is given to certain medical devices that provide treatment or diagnosis of life-threatening conditions. It is aimed at speeding up development and review of devices currently under development. The experimental...
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
Sep 21, 2024
On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s flagship oral medical device, which is used to treat moderate to severe obstructive sleep apnea (OSA) and snoring in children. Recent published studies report up to 10.1 million U.S. children (ages 6-17) are estimated to suffer from pediatric OSA. Vivos’ DNA appliance is non-invasive, safe, comfortable, affordable, and highly effective....
Germany's Commerzbank has a bumpy history with big M&A
Germany's Commerzbank has a bumpy history with big M&A
Sep 21, 2024
FRANKFURT (Reuters) -Commerzbank is poised to put CFO Bettina Orlopp in charge of talks with UniCredit when the German bank's supervisory board meets next week, two people with knowledge of the matter said, as the Italian rival considers a takeover. Commerzbank has, like some other banks, had a rocky history with big mergers and acquisitions over the years. These are...
Copyright 2023-2026 - www.financetom.com All Rights Reserved